TRADENAME (Citalopram HBr) Orally Disintegrating Tablets

Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in shortterm studies in children and adolescents with Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of [Insert established name] or any other antidepressant in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. TRADENAME is not approved for use in pediatric patients. (See Warnings and Precautions: Pediatric Use)